NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Wednesday announced that its Phase 4 clinical study involving PRISTIQ, showed low potential for sexual dysfunction in adults with major depressive disorder or MDD. Sexual dysfunction is often an issue for patients treated with antidepressants.
The primary end point of the trial showed a statistically significant improvement among patients treated with PRISTIQ compared to placebo in symptoms of major depressive disorder as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score over an 8-week period.
The study was published in the Journal of Clinical Psychiatry, and was carried out following a post marketing requirement by the U.S. Food and Drug Administration or FDA.
Copyright RTT News/dpa-AFX